Belumosudil

Small molecule

Also known as KD025

Approvedregulatory verdict

Evidence outlook

Approved: Chronic Graft-versus-Host Disease, Graft-versus-Host Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Weak signal

Also approved (3)
EU
  • Rezurock is indicated for the treatment of adults and paediatric patients (12 years and older with a body weight of at least 40 kg) with chronic graft-versus-host disease (cGVHD) when other treatment options provide limited clinical benefit, are not suitable, or have been exhausted.
Product first approved 2026EMA
JP
  • Treatment of chronic graft-versus-host disease after hematopoietic stem cell transplantation (for use when steroid drugs are not sufficiently effective)
Product first approved 2024PMDA
CA
  • REZUROCK is indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy. Efficacy in patients with chronic GVHD was based on objective response rate and duration of response in a single-arm study (see 14 CLINICAL TRIALS).
Product first approved 2022Health Canada

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Chronic Graft-versus-Host Disease
Other / comorbidity
NCT06082037 · Sanofi
2023-10-10 – 2030-10-01 · Lung Transplant Rejection
What this study did
Phase 2 (18)
Chronic Graft-versus-Host Disease
NCT07116031 · Sanofi
2025-12-02 – 2031-02-28 · Chronic Graft Versus Host Disease
What this study did
NCT07643025 · Dennis Kim
2026-11 – 2030-11 · cGVHD
What this study did
NCT05996627 · Fred Hutchinson Cancer Center
2023-12-06 – 2028-11-30 · Chronic Graft Versus Host Disease
What this study did
NCT05922761 · Dana-Farber Cancer Institute
2024-05-31 – 2027-12-31 · Bronchiolitis Obliterans Syndrome, Bronchiolitis Obliterans, Lung Diseases, Chronic Graft Versus Host Disease
What this study did
NCT06046248 · Northside Hospital, Inc.
2024-01-29 – 2027-12-31 · Chronic Graft Versus Host Disease
What this study did
NCT05305989 · Kadmon, a Sanofi Company
2022-02-23 – 2024-06-06 · Chronic Graft-versus-host-disease
What this study did
NCT02841995 · Kadmon, a Sanofi Company
2016-09-15 – 2022-05-12 · Graft vs Host Disease
What this study did
Graft-versus-Host Disease
NCT07006506 · Memorial Sloan Kettering Cancer Center
2025-05-21 – 2029-05-21 · Graft Versus Host Disease, Graft Vs Host Disease, Hematologic Malignancy
What this study did
Other / comorbidity
NCT06751602 · The Methodist Hospital Research Institute
2025-09-11 – 2028-03-30 · Rejection Chronic Renal
What this study did
NCT06476132 · National Institute of Allergy and Infectious Diseases (NIAID)
2025-03-12 – 2027-06-30 · Lung Transplant
What this study did
NCT03919799 · Kadmon, a Sanofi Company
2019-06-26 – 2023-02-17 · System; Sclerosis, Diffuse Cutaneous Systemic Sclerosis
What this study did
NCT04680975 · Kadmon, a Sanofi Company
2021-03-03 – 2022-12-19 · Diffuse Cutaneous Systemic Sclerosis
What this study did
NCT02688647 · Kadmon Corporation, LLC
2016-05-26 – 2021-04-13 · Idiopathic Pulmonary Fibrosis
What this study did
NCT02852967 · Kadmon Corporation, LLC
2016-09-14 – 2019-02-13 · Chronic Plaque Psoriasis
What this study did
NCT02317627 · Kadmon Corporation, LLC
2014-12 – 2016-03 · Psoriasis Vulgaris
What this study did
NCT02106195 · Kadmon Corporation, LLC
2014-04 – 2014-09 · Psoriasis Vulgaris
What this study did
Phase 1/2 (2)
Other / comorbidity
NCT06105554 · M.D. Anderson Cancer Center
2024-01-30 – 2029-08-31 · Multiple Myeloma
What this study did
NCT04643002 · Sanofi
2021-01-25 – 2028-04-20 · Plasma Cell Myeloma Refractory
What this study did
Phase 1 (13)
Chronic Graft-versus-Host Disease
NCT07127926 · M.D. Anderson Cancer Center
2026-02-09 – 2027-12-31 · Chronic Graft Versus Host Disease
What this study did
NCT07726914 · Sanofi
2026-11-17 – 2027-01-26 · Chronic Graft Versus Host Disease
What this study did
Other / comorbidity
NCT05806749 · University of California, Los Angeles
2023-07-07 – 2028-08 · End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases
What this study did
NCT07484113 · Stanford University
2026-09 – 2028-05 · cGVHD
What this study did
NCT05806567 · Kadmon, a Sanofi Company
2022-07-27 – 2022-10-28 · Immune System Disorder, Healthy Volunteers
What this study did
NCT04166942 · Kadmon, a Sanofi Company
2019-12-11 – 2022-06-06 · Hepatic Impairment
What this study did
NCT04735822 · Kadmon Corporation, LLC
2020-10-26 – 2021-09-03 · Healthy Volunteers
What this study did
NCT03907540 · Kadmon Corporation, LLC
2019-04-05 – 2019-05-20 · Autoimmune Diseases, Fibrosis
What this study did
NCT03530995 · Kadmon Corporation, LLC
2018-04-09 – 2019-02-08 · Drug-drug Interaction, Autoimmune Diseases, Fibrotic Disease
What this study did
NCT02557139 · Kadmon Corporation, LLC
2015-09 – 2015-10-12 · Bioavailability
What this study did
NCT05918614 · Kadmon, a Sanofi Company
2014-03-28 – 2014-06-07 · Immune System Disorder (Healthy Volunteer)
What this study did
NCT05918588 · Kadmon, a Sanofi Company
2013-11-21 – 2014-03-06 · Immune System Disorder (Healthy Volunteer)
What this study did
NCT05918627 · Kadmon, a Sanofi Company
2009-09-21 – 2009-12-09 · Immune System Disorder (Healthy Volunteer)
What this study did
Phase 4 (2)
Chronic Graft-versus-Host Disease
NCT07135973 · Sanofi
2026-11-20 – 2028-03-17 · Chronic Graft Versus Host Disease
What this study did
Early phase / not applicable (2)
Other / comorbidity
NCT07794514 · First Affiliated Hospital of Zhejiang University
2026-10-01 – 2030-12-31 · Hematopoietic Stem Cell Transplantation (HSCT), cGVHD, Hepatic cGVHD, Belumosudil, Ruxolitinib
What this study did
NCT06509490 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2024-07-17 – 2026-03-26 · Safety Issues
What this study did

Competitive landscape

Other Rho-associated kinase (ROCK, pan) drugs

ROC-101. Compare all 2 Rho-associated kinase (ROCK, pan) drugs

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Chronic Graft-versus-Host Disease: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Belumosudil: this drugApprovedSmall moleculeRho-associated kinase (ROCK, pan)Weak signal
NCT03640481: Overall Response Rate (ORR) (From the date of randomization to the date of first documentation of progression or death due to any cause or data cut-off, whichever occurred first (maximum duration: up to 40.5 months for adult arms and 27.6 months for adolescent arms)): Adult Arm A: Belumosudil 200 mg QD 74 Percentage of participants | Adult Arm B: Belumosudil 200 mg BID 76 Percentage of participants | Adolescent Arm A: Belumosudil 200 mg QD 50 Percentage of participants | Adolescent Arm B: Belumosudil 200 mg BID 100 Percentage of participants
AxatilimabApprovedMonoclonal antibodyCSF-1RWeak signalFeatured results are non-efficacy only in this race
IbrutinibApprovedSmall moleculeBTKnot yet gradedNo reviewed efficacy summary in this indication
Ruxolitinib (Jakafi)ApprovedSmall moleculeJAK1/2Partial signal
NCT03112603: Efficacy of Ruxolitinib Versus Investigator's Choice Best Available Therapy (BAT) in Participants With Moderate or Severe Steroid Refractory Chronic Graft Versus Host Disease (SR-cGvHD) Assessed by Overall Response Rate (ORR) at the Cycle 7 Day 1 Visit (Cycle 7 Day 1 (each cycle was comprised of 4 weeks)): Ruxolitinib 49.7 percentage of participants (95% CI 41.8 to 57.6) | Best Available Therapy 25.6 percentage of participants (95% CI 19.1 to 33)
ROC-101
Phase 2(overall)
Small moleculeRho-associated kinase (ROCK, pan)
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(18 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Belumosudil to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (8)
January 2027 (1)
Phase 1Chronic Graft-versus-Host DiseaseNot yet recruiting
Est. primary completion 2027-01-26 · NCT07726914 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2Lung TransplantRecruiting
Est. primary completion 2027-05-30 · NCT06476132 · CT.gov ↗
What to watch
June 2027 (1)
Phase 2Chronic Graft-versus-Host DiseaseRecruiting
Est. primary completion 2027-06-30 · NCT05922761 · CT.gov ↗
What to watch
August 2027 (2)
Phase 4Chronic Graft-versus-Host DiseaseNot yet recruiting
Est. primary completion 2027-08-30 · NCT07135973 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-08-31 · NCT06105554 · CT.gov ↗
What to watch
September 2027 (1)
Phase 1/2Plasma Cell Myeloma RefractoryRecruiting
Est. primary completion 2027-09-13 · NCT04643002 · CT.gov ↗
What to watch
December 2027 (2)
Phase 2Rejection Chronic RenalEnrolling by invitation
Est. primary completion 2027-12 · NCT06751602 · CT.gov ↗
What to watch
Phase 1Chronic Graft-versus-Host DiseaseRecruiting
Est. primary completion 2027-12-31 · NCT07127926 · CT.gov ↗
What to watch
2028 (5)
April 2028 (1)
Phase 2Chronic Graft-versus-Host DiseaseRecruiting
Est. primary completion 2028-04-30 · NCT05996627 · CT.gov ↗
What to watch
May 2028 (1)
Phase 1cGVHDNot yet recruiting
Est. primary completion 2028-05 · NCT07484113 · CT.gov ↗
What to watch
August 2028 (1)
Phase 1End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney DiseasesActive not recruiting
Est. primary completion 2028-08 · NCT05806749 · CT.gov ↗
What to watch
September 2028 (2)
Phase 2Chronic Graft-versus-Host DiseaseRecruiting
Est. primary completion 2028-09-25 · NCT07116031 · CT.gov ↗
What to watch
Phase 3Chronic Graft-versus-Host DiseaseActive not recruiting
Est. primary completion 2028-09-29 · NCT06143891 · CT.gov ↗
What to watch
2029 (4)
January 2029 (1)
Phase 3Lung Transplant RejectionRecruiting
Est. primary completion 2029-01-29 · NCT06082037 · CT.gov ↗
What to watch
May 2029 (1)
Phase 2Graft-versus-Host DiseaseRecruiting
Est. primary completion 2029-05-21 · NCT07006506 · CT.gov ↗
What to watch
September 2029 (1)
Phase 3Chronic Graft-versus-Host DiseaseRecruiting
Est. primary completion 2029-09-14 · NCT07771439 · CT.gov ↗
What to watch
November 2029 (1)
Phase 2Chronic Graft-versus-Host DiseaseNot yet recruiting
Est. primary completion 2029-11 · NCT07643025 · CT.gov ↗
What to watch
2030 (1)
April 2030 (1)
Early phase / not applicableHematopoietic Stem Cell Transplantation (HSCT), cGVHD, Hepatic cGVHD, Belumosudil, RuxolitinibRecruiting
Est. primary completion 2030-04-01 · NCT07794514 · CT.gov ↗
What to watch

See the full readout calendar ↗